Texas signals support for unproven stem cell therapies.
作者信息
Servick Kelly
出版信息
Science. 2017 Jun 23;356(6344):1219. doi: 10.1126/science.356.6344.1219.
Abstract
摘要
相似文献
1
Texas signals support for unproven stem cell therapies.得克萨斯州表明对未经证实的干细胞疗法的支持。
Science. 2017 Jun 23;356(6344):1219. doi: 10.1126/science.356.6344.1219.
2
Stem cells. Texas Medical Board approves rules for controversial treatment.干细胞。德克萨斯州医学委员会批准了针对有争议治疗方法的规定。
Science. 2012 Apr 20;336(6079):284. doi: 10.1126/science.336.6079.284.
3
[Advanced therapy medicinal products : Scientific, medical, economic, and ethical aspects].[先进治疗医药产品：科学、医学、经济和伦理方面]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2011 Jul;54(7):789-90. doi: 10.1007/s00103-011-1311-4.
4
Texas stem cell rules may impede clinical research.德克萨斯州的干细胞规定可能会阻碍临床研究。
Lancet. 2012 May 12;379(9828):1776. doi: 10.1016/s0140-6736(12)60744-2.
5
Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions.简明综述：接受未经证实的干细胞干预治疗的患者报告不良事件的综合分析。
Stem Cells Transl Med. 2018 Sep;7(9):676-685. doi: 10.1002/sctm.17-0282. Epub 2018 Jul 31.
6
Texas H.B. 810: Increased Access to Stem Cell Interventions or an Increase in Unproven Treatments?德克萨斯州 H.B. 810：增加干细胞干预措施的可及性还是增加未经证实的治疗方法？
Stem Cells Dev. 2018 Nov 1;27(21):1463-1465. doi: 10.1089/scd.2018.0148. Epub 2018 Sep 8.
7
Medical innovation versus stem cell tourism.医学创新与干细胞旅游
Science. 2009 Jun 26;324(5935):1664-5. doi: 10.1126/science.1171749.
8
The Need for Beneficence and Prudence in Clinical Innovation with Autologous Stem Cells.自体干细胞临床创新中对行善和审慎的需求。
Perspect Biol Med. 2018;61(1):90-105. doi: 10.1353/pbm.2018.0029.
9
Improving oversight of innovative medical interventions in Texas, USA.加强对美国得克萨斯州创新医疗干预措施的监管。
Regen Med. 2012 Jul;7(4):451-3. doi: 10.2217/rme.12.43.
10
Unproven stem cell therapies: is it my right to try?未经证实的干细胞疗法：我有权尝试吗？
Ann Ist Super Sanita. 2019 Apr-Jun;55(2):179-185. doi: 10.4415/ANN_19_02_10.
引用本文的文献
1
Four Food and Drug Administration draft guidance documents and the REGROW Act: A litmus test for future changes in human cell- and tissue-based products regulatory policy in the United States?美国食品和药物管理局的四份指导文件草案和《再生法案》：这是对未来美国人类细胞和组织为基础的产品监管政策变化的试金石吗？
J Tissue Eng Regen Med. 2018 Jul;12(7):1579-1593. doi: 10.1002/term.2683. Epub 2018 May 21.
Zotero 插件